Hepatitis B Trial, Recruiting (NCT07275554)

Hepatitis B Trial, Recruiting NCT07275554 Sponsor: Qilu Hospital of Shandong University Condition: Hepatitis B

Printed from Voxsanity (voxsanity.com.au) — NCT07275554 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis B

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have had a positive hepatitis B surface antigen (a blood marker showing hepatitis B infection) for more than six months, which indicates a long-term hepatitis B infection
People who have been diagnosed with liver scarring (cirrhosis) caused by hepatitis B, confirmed through a tissue sample, imaging scan, endoscopy, or medical history
People who have a serious liver condition called acute-on-chronic liver failure related to hepatitis B, meeting specific guidelines from the Asia-Pacific region (2018), including high levels of bilirubin (a substance that causes jaundice) in the blood and abnormal blood clotting results (confirm with trial site)

Who may not be able to join:

People who also have an infection with another type of hepatitis virus (such as hepatitis C or D)
People who have a history of liver cancer or any other type of cancer
People who have an autoimmune liver disease (a condition where the immune system attacks the liver) alongside their hepatitis B
People whose medical records do not contain enough information for the trial team to assess their condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0086+053182169593

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07275554

Sponsor: Qilu Hospital of Shandong University

Phase: Not Applicable

Status: Recruiting

Condition: Hepatitis B

Trial contact: 0086+053182169593

More information: https://clinicaltrials.gov/study/NCT07275554

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have had a positive hepatitis B surface antigen (a blood marker showing hepatitis B infection) for more than six months, which indicates a long-term hepatitis B infection
People who have been diagnosed with liver scarring (cirrhosis) caused by hepatitis B, confirmed through a tissue sample, imaging scan, endoscopy, or medical history
People who have a serious liver condition called acute-on-chronic liver failure related to hepatitis B, meeting specific guidelines from the Asia-Pacific region (2018), including high levels of bilirubin (a substance that causes jaundice) in the blood and abnormal blood clotting results (confirm with trial site)

Who may not be able to join:

People who also have an infection with another type of hepatitis virus (such as hepatitis C or D)
People who have a history of liver cancer or any other type of cancer
People who have an autoimmune liver disease (a condition where the immune system attacks the liver) alongside their hepatitis B
People whose medical records do not contain enough information for the trial team to assess their condition

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Qilu Hospital of Shandong University

Registry

ClinicalTrials.gov

Start date

31 December 2024

Est. completion

31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Analysis of Methylomic Features in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov